

Everolimus for advanced renal cell carcinoma after previous treatment

Information for the public
Published: 22 February 2017

www.nice.org.uk

What has NICE said?

Everolimus (Afinitor) is recommended as a possible treatment for advanced renal cell carcinoma that has got worse during or after a type of treatment called vascular endothelial growth factor targeted therapy.

What does this mean for me?

If you have renal cell carcinoma, and your doctor thinks that everolimus is the right treatment, you should be able to have it on the NHS.

The condition and the treatment

Renal cell carcinoma is a kidney cancer that starts in the cells lining the small tubes that help to make urine. In advanced disease, the cancer has spread inside the kidney, and may have spread outside the kidney.

Everolimus is a drug that helps the body's immune system to recognise and destroy cancer cells.

[NHS Choices](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Kidney Research UK](#), 0300 303 1100
- [British Kidney Patient Association](#), 01420 541 424
- [Kidney Cancer UK](#), 0800 002 9002
- [National Kidney Federation](#), 0845 601 0209
- [Kidney Cancer Support Network](#), 01209 890326

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2347-2

Accreditation

